Pay in 4 interest-free payments of $9.00 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
135897-06-2
LY3200882 inhibits NIH3T3 cell viability with an IC50 of 82
FCCP does not alter cellular ATP levels at any of the concentrations measured
is activated upon DNA damage and plays a key role in repairing double-stranded DNA breaks via the DNA nonhomologous end joining (NHEJ) pathway
17R)-6-ethyl-3
Abiraterone - CYP17 inhibitor Abiraterone (CB-7598). CAS# 154229-19-3 one Demethylase 135897-06-2Abiraterone, CAS No. 154229 19 3, is the first in class potent and selective CYP17 (cytochrome P450 17alpha hydroxylase 17, 20 lyase) inhibitor with IC50 ~4 nM. It was approved by US FDA in 2011 to treat castration resistant prostate cancer. As prostate cancer cells proliferate in response to androgen steroids, CYP17 inhibition is a new strategy to prevent androgen synthesis and treat lethal metastatic prostate cancer. In recent Nature publication,